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Abstract 
Purpose: Patients with chronic haemolytic anaemia, such as in thalassaemia, require repeated blood transfusions, 
which leads to iron overload and cellular damage, especially in the heart and liver. Classically, serum ferritin and 
liver biopsy have been used to monitor patient response to chelation therapy. Magnetic resonance imaging (MRI) 
has proven to be effective in detecting and quantifying iron in the heart and liver. The aim of the paper is to evaluate 
the accuracy of the MRI T2* procedure in the assessment of liver iron concentration and myocardial iron overload.
Material and methods: In 210 cases of monthly transfused patients, hepatic and myocardial iron overload was meas-
ured by multi-breath-hold MRI T2* and compared to serum ferritin (a traditional marker of iron overload).
Results: No significant correlation was observed between serum ferritin level and cardiac T2* MRI (p = 0.68,  
r = 0.06). However, a significant correlation was observed between serum ferritin and liver iron concentration eval-
uated by MRI (p = 0.04, r = 0.68).
Conclusion: Routine evaluation of liver and heart iron content using MRI T2* is suggested to better evaluate the hae-
mosiderosis status in thalassaemic patients.
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Introduction
Iron is an essential element that forms a vital component 
of metabolic and biological processes, but when present 
in excess it can yield tissue damage due to oxidative stress. 
Patients with thalassaemia require regular blood transfu-
sions to survive beyond the second decade of life [1-3]. 
Even though transfusions improve health and survival, 
the chronic administration of large amounts of blood, 
along with extra vascular haemolysis and an increase in 
the intestinal absorption of iron, inevitably leads, despite 
chelation therapy, to significant haemosiderosis of all or-
gans [4]. Excess body iron may accumulate in the liver, 
spleen, heart, bone marrow, pituitary, pancreas, and the 
central nervous system, initiating damage to these organs 
[5]. Iron overload cardiomyopathy (IOC) results from the 
accumulation of iron in the myocardium, and it frequently 
ensues late and can be difficult to reverse once established, 
and it is a significant cause of death in patients in receipt 
of chronic blood transfusion therapy [6,7]. Inopportune-
ly, significant cardiac iron burden can happen regardless 
of low liver iron concentration [8]. There is significant 
clinical importance to reliably risk stratify patients for the 
development of heart failure, so that chelation therapy 
can be increased and cardiac morbidity averted [9]. Indi-
rect markers of current cardiac iron overloading, namely 
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single measurements of serum ferritin and biopsy-deter-
mined liver iron concentration, are inadequate for identi-
fying myocardial iron deposition in chronically transfused 
patients [1-3,10].
Ferritin is a metalloprotein that is found in cells. It 
stores and releases iron in a controlled manner. In nor-
mal individuals, a small amount appears in the circulation 
and in general reflects the total body iron. Normal values 
of serum ferritin for men and women are 12-300 ng/ml 
and 12-150 ng/ml, respectively [1-3]. It is an acute phase 
reactant, and the serum levels may be disproportionate-
ly greater than the degree of iron loading in infections, 
inflammatory states, liver dysfunction, and malignancies 
[1-3]. However, magnetic resonance can measure the 
paramagnetic properties of tissue iron to provide direct, 
non-invasive iron assessments, and clinically this has been 
achieved by assessing the T2 and T2* relaxation param-
eters [11]. Magnetic resonance does not image the iron 
directly but instead images water protons as they diffuse 
near iron deposits in the tissue of interest [8]. The iron 
acts as small magnets, extinguishing the homogeneity of 
the magnetic field in iron-laden tissues. The moving water 
protons experience significantly dissimilar magnetic pro-
files and become desynchronised from one another. This 
causes the image to darken at a level proportional to the 
iron concentration [12]. This technique is unassuming, al-
lowing fast and reproducible quantification of myocardial 
and hepatic iron, consequently allowing pre-symptomatic 
detection of myocardial siderosis [13]. The T2* technique 
has the potential to become a noninvasive standard tech-
nique in evaluating tissue iron [10-12]. In the present 
study, we also compared the MRI T2* results with serum 
ferritin levels of patients on regular blood transfusion.
Material and methods
Cardiac T2* and liver iron concentration (LIC) measure-
ments were performed on 210 thalassaemia major patients 
(110 males and 100 females, age 11.1 ± 9.8 years) who re-
ceived regular transfusion and iron chelation therapy with 
serum ferritin levels > 1000 ng/ml. Patients with a con-
traindication to magnetic resonance imaging, including 
pacemakers, claustrophobia, and inability to comply with 
the instructions, were excluded from the study. Approval 
was obtained from the Ethics Committee of the Faculty 
of Medicine.
Magnetic resonance imaging interpretation 
The images were acquired on a 1.5-T Avanto system (Sie-
mens Medical Solutions, Erlangen, Germany) following 
a standard protocol system using a cardiac phased-ar-
ray coil. Each patient was scanned using both the opti-
mised bright-blood [14,15] and the original black-blood 
sequences [16]. In summary, each technique is a cardi-
ac-gated, multi-echo, fast gradient sequence acquired 
within a single breath-hold. The black-blood technique 
employs an additional double inversion recovery pre-
pulse to null the blood signal in the heart chamber. 
A single midventricular short-axis slice was acquired 
with a slice thickness of 6 and 10 mm for the black blood 
techniques. Imaging parameters were a TR of 19 ms, eight 
echo times (2.616.74 ms with 2.02-ms steps), a matrix of 
128 x 256, and a FOV of 40 cm, which yielded a voxel 
size of 3.1 x 1.6 x 10 mm3, while the inversion time (TI) 
was set to suppress the blood signal. The acquired images 
were analysed locally and also transferred in DICOM for-
mat to be processed at the reference site. All T2* analyses 
were performed independently at the site using individ-
ual, custom software developed in MATLAB (The Math-
Work, Natick, MA) [14,15]. All image data were fit to the 
offset model at the reference site (REF-offset) and fit to the 
offset (LOC-offset) and mono-exponential (LOC-typical) 
models at the local site. ROIs had been defined, manual-
ly, from the whole interventricular septum (WS) at the 
reference site, as in the conventional method, and from 
the partial interventricular septum (PS) region using prior 
knowledge of a T2* map to avoid susceptibility artefacts 
and partial volume effect at the edge of the septum, as 
suggested in previous studies [14-16]. A radiologist with 
more than 10 years’ experience in cardiac MR analysis in-
dependently performed the analyses. The T2* results of 
all models in this study were reported by using both their 
mean and median values. The result from a typical LOC 
method reported by its median is, therefore, equivalent to 
the MPS-PW method. For the measurement of liver T2*, 
a single trans-axial slice through the centre of the liver was 
imaged at eight echo times (2.3-16 ms). The TR was set to 
200 ms without cardiac gating. Signal intensity analysis 
was performed in the periphery of the liver away from the 
large central vessels. 
The cut-off points in this MRI instrument were as fol-
lows for liver iron concentrations (LIC): normal ≤ 3 mg 
Fe/g dw, mild 3-7 mg Fe/g dw, moderate 7-15 mg Fe/g dw, 
and severe ≥ 15 mg Fe/g dw (Figure 1).
Cardiac T2*: normal > 25 msec, marginal 20-25 msec, 
mild to moderate 10-20 msec, and severe ≤ 10 msec (Fig-
ure 2).
Serum ferritin levels
Measurements were carried out using a microparticle 
enzyme immunoassay (MEIA; Abbot Diagnostics, IMX 
System, Ferritin, IL, USA).
Statistical analysis
Statistical analysis was performed with commercially 
available software (SPSS Inc., version 18.0, Chicago, IL, 
USA). A paired Student’s t-test was selected to evaluate 
the difference between the two data. A p value less than 
0.05 was considered to be significant.
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Results
Patients
Cardiac T2* and liver iron concentration measurements 
were performed on 210 thalassemia major patients (110 ma - 
les and 100 females, age 11.1 ± 9.8 years). Splenectomy 
had been performed in 12 of the patients. All patients had 
received iron chelation therapy from early childhood for 
a median duration of 18 months. 
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Serum ferritin levels versus myocardial T2* and liver iron 
concentration values
Serum ferritin ranged between 298 and 14,827. About 
17% of the patients showed mildly elevated ferritin level, 
while equal percentages (41%) had moderate and severe 
high ferritin levels. Myocardial T2* ranged from 48.1 to 
7.1 and was at normal level among the majority of the 
patients (81.4%), 7.1% presented with marginal and mild 
to moderate each, and 4.3% had severe myocardial iron 
overload (Table 1). The liver iron concentration ranged 
from 0.7 to 27.9, about third of the patients showed mild 
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and severe levels (30.0% and 35.7%, respectively), moder-
ate liver iron concentration was seen in 21.4%, while only 
12.9% showed normal hepatic iron load (Table 2). Serum 
ferritin levels showed a significant negative correlation 
with the liver T2* values (p = 0.01, r = 0.318). No sig-
nificant correlation was observed between serum ferritin 
level and cardiac T2* MRI (p = 0.68, r = 0.06). Neverthe-
less, a significant correlation was observed between serum 
ferritin and liver iron concentration evaluated by MRI 
(p = 0.04, r = 0.68).
Discussion
The assessment of tissue iron is vital for the determination 
of clinical outcomes, determining when to start chelation, 
and for selection of the regime that should be prescribed. 
The quantitative determination of the deposition of iron 
in various organs in multi-transfused patients with thalas-
saemia is of extreme importance for the effective monitor-
ing of iron chelation therapy [17]. Until recently, liver iron 
concentration was quantitated by biopsy, and measure-
ment of ferritin levels patients in steady state has been the 
only method available to this effect. Nevertheless, ferritin 
levels alone are not completely acceptable because they 
may demonstrate considerable variations due to inflam-
mation, infection, or other chronic disorders. Further-
more, there have been instances of heavy iron deposition 
in which the serum ferritin levels were disproportionately 
low [8,9]. Tissue biopsy is the traditional gold standard for 
making the diagnosis of myocardial iron overload [18], 
but iron deposition has a tendency to be patchy [8,9]. 
Endomyocardial biopsies may therefore miss the areas of 
deposition and provide a false negative result; also, it is an 
invasive and hazardous procedure [18]. The discomfort 
and risk that a liver biopsy causes to the patients together 
with the weak correlation between liver fibrosis and iron 
concentration reduces the value of this examination, espe-
cially when this has to be repeated regularly [8,11]. Hence, 
it is not surprising that alternative, noninvasive, but accu-
rate methods for the assessment of iron deposition have 
been sought in recent years. Serial assessment of liver 
and cardiac iron determines that cardiac iron changes lag 
behind changes in liver iron concentration. The liver is 
the foremost storage organ for excess iron and willingly 
acquires excess transferrin- and non-transferrin-bound 
iron; it also mobilises iron rapidly and proficiently in 
times of mandate or in response to iron chelation. Con-
versely, the heart has vigorous mechanisms to prevent ex-
cess transfer-mediated uptake [19]. Pathologic myocardial 
iron overload occurs when the iron binding capacity is 
saturated and labile free iron species begin to circulate. 
Even then, cardiac iron uptake is delayed compared to 
many other extrahepatic organs, including the pancreas. 
Therefore, many young patients can display severe he-
patic iron overloading with no evidence of cardiac iron 
overloading [20]. T2* is an essential MRI relaxation time 
Table 1. Relationship between serum ferritin levels and myocardial T2*
Myocardial T2* Number of patients Serum ferritin levels
Normal 171 1911 ± 351
Marginal 15 2084 ± 443
Mild to moderate 15 731 ± 342
Severe 9 4572 ± 908




Number of patients Serum ferritin levels
Normal 27 1230 ± 355
Mild 63 1766 ± 390
Moderate 45 2489 ± 479
Severe 75 4999 ± 2033
that shortens in the presence of iron. It is non-invasive, 
cost-effective, with no radiation exposure, and has wide-
spread accessibility [21]. Anderson et al. were the first to 
use the T2* technique for myocardial iron assessment 
in subjects with thalassaemia major [2]. It was seen that 
there was a progressive decline in the ejection fraction of 
the heart as the myocardial iron deposition increased, and 
all patients with ventricular dysfunction had a myocardial 
T2* of less than 20 ms [18]. The purpose of the present 
study was to reassess the effectiveness of MRI in meas-
uring the amount of iron deposited in the heart and liver 
of regularly transfused patients with thalassaemia in an 
endemic area. We included 210 patients with thalassemia 
major, and all patients were on a regular transfusion pro-
gram and had been on iron chelation therapy for at least 
18 months. The present study also revealed a correlation 
between liver iron concentration and serum ferritin levels 
in all patients, which is consistent with the results of Kalt-
wasser et al. and Fischer [8,22]. No significant correlation 
was found between serum ferritin levels and myocardial 
T2*, and there was a moderate negative correlation be-
tween serum ferritin and liver iron concentration evalu-
ated by MRI in our study. Several other studies have found 
dissimilar correlation strengths, ranging from no correla-
tion to low correlation, between serum ferritin and heart 
iron content; all have found that serum ferritin cannot sat-
isfactorily evaluate cardiac haemosiderosis [23,24]. Such 
results therefore underscore the importance of MRI T2* 
as a more accurate method for estimating liver and heart 
iron overload. Five cases showed severe cardiac overload 
with mild liver iron overload and no corresponding high 
serum ferritin levels. There have been reports of heavy 
cardiac iron deposition in spite of the presence of low se-
rum ferritin levels [2,25]. Noetzli et al. disclosed that low 
values of liver iron or serum ferritin do not certainly sig-
nify low-risk of iron-induced cardiomyopathy. This may 
arise because iron chelation therapy can eliminate iron 
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more rapidly from the liver than from the heart, which 
may normalise liver iron while myocardial iron remains 
high [7]. T2* has been associated with myocardial and 
hepatic iron concentration in previous studies, including 
direct biopsies. Recently, cardiac and liver iron evaluations 
by MRI have become the primary outcome measures for 
clinical studies of iron chelation therapy [21,26]. Ha et al. 
[27] stated that liver biopsies are now outdated in thalas-
saemia cases, except for histological assessment of viral 
hepatitis. Our study has limitations due to the relative-
ly small number of patients and lack of consideration of 
prevailing factors that may affect the serum ferritin levels, 
such as C-reactive protein, white blood cell count, and 
liver function tests.
Conclusions
MRI T2* provides a precise, reproducible, and non-inva-
sive technique for measuring tissue iron concentration, 
sparing the patients from invasive biopsy. Through the 
widespread application of this technique it should be pos-
sible to improve the management of tissue iron overload, 
and in particular aid the presymptomatic recognition of 
myocardial siderosis, allowing earlier chelation intensifi-
cation with its potential for reduced cardiac events.
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